Wegovy vs Zepbound: Comparing the Two Weight-Reduction Labels

    Short answer

    Wegovy (semaglutide, Novo Nordisk) acts on the GLP-1 receptor; Zepbound (tirzepatide, Eli Lilly) acts on GIP and GLP-1 receptors. Both labels cover long-term weight reduction. Wegovy adds heart risk reduction and MASH; Zepbound adds obstructive sleep apnea. In the open-label SURMOUNT-5 trial, average weight loss was larger with tirzepatide.

    Wegovy contains semaglutide and is made by Novo Nordisk, while Zepbound contains tirzepatide and is made by Eli Lilly. Both labels include long-term weight reduction for adults with obesity, or overweight with a weight-related condition. Below, the Wegovy label (revised 06/2026) and the Zepbound label (revised 08/2026) sit side by side with the published SURMOUNT-5 head-to-head trial. The decision itself is one to make with your prescriber, so nothing here names a winner.

    The Short Answer

    One Hormone Pathway or Two

    Wegovy acts on the GLP-1 receptor. Zepbound acts on both the GIP and GLP-1 receptors, as its label describes it.

    Different Extra Uses

    Beyond weight reduction, Wegovy is approved to lower heart event risk in adults with heart disease and for a liver condition called MASH. Zepbound is also approved for moderate to severe obstructive sleep apnea in adults with obesity.

    A Published Head-to-Head Trial

    In SURMOUNT-5, one open-label trial, adults with obesity lost an average of 20.2% of body weight on tirzepatide and 13.7% on semaglutide over 72 weeks. Averages are not promises, and the trial has limits covered below.

    Shot or Tablet

    Zepbound is a once-weekly injection. Wegovy comes as a once-weekly injection or a once-daily tablet, each with its own steps on the same label.

    Wegovy and Zepbound at a Glance

    One row per label fact, from the Wegovy and Zepbound prescribing information.

    WegovyZepbound
    IngredientSemaglutideTirzepatide
    MakerNovo NordiskEli Lilly
    ReceptorsGLP-1GIP and GLP-1
    Approved usesWeight reduction (adults; children 12+ for the injection); heart risk reduction; MASH (injection)Weight reduction (adults); obstructive sleep apnea in adults with obesity
    FormsWeekly injection (pens, syringes, FlexTouch); daily tabletWeekly injection: single-dose pen or vial, multi-dose vial or KwikPen

    Approved Uses in Full

    Wegovy injection is approved for weight reduction in adults and in children 12 and older with obesity, and in adults with overweight and a weight-related condition. It is also approved for heart event risk reduction in adults with heart disease and obesity or overweight, and for MASH with moderate to advanced liver scarring.

    Zepbound is approved for weight reduction in adults with obesity, or overweight with at least one weight-related condition. It is also approved for moderate to severe obstructive sleep apnea in adults with obesity.

    Forms and How Often

    Zepbound comes in single-dose pens, single-dose vials, multi-dose vials or a multi-dose KwikPen, taken once a week. Wegovy injection comes in single-dose pens, single-dose syringes or a multi-dose FlexTouch pen once a week, and Wegovy tablets are taken once a day on an empty stomach.

    The Diabetes Brands With the Same Ingredients

    Semaglutide is also sold as Ozempic and tirzepatide as Mounjaro, each with its own diabetes label. The Mounjaro vs Ozempic comparison covers those two.

    Who Should Not Use Either One

    Both labels rule out anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2. Both also rule out a known allergy to the active ingredient or the product's other ingredients.

    Using Them Together

    Both labels say combining the medicine with any other GLP-1 receptor agonist is not recommended. Wegovy and Zepbound are not meant to be taken together.

    What the SURMOUNT-5 Trial Found

    Every figure is a group average from one open-label trial at 72 weeks.

    Average result, 72 weeks, one open-label trialTirzepatideSemaglutide
    Doses studied (highest tolerated)10 mg or 15 mg weekly1.7 mg or 2.4 mg weekly
    Average body weight change-20.2%-13.7%
    Average waist change-18.4 cm-13.0 cm

    How the Trial Was Set Up

    SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes to the highest dose they could tolerate of tirzepatide, 10 mg or 15 mg, or semaglutide, 1.7 mg or 2.4 mg, once weekly for 72 weeks. Results were published in the New England Journal of Medicine in July 2025.

    Weight and Waist Results

    Average weight fell by 20.2% on tirzepatide and 13.7% on semaglutide. Average waist size fell by 18.4 cm and 13.0 cm, and more people on tirzepatide reached 10%, 15%, 20% and 25% weight reductions.

    Side Effects in the Trial

    The most common side effects in both groups were stomach-related. Most were mild to moderate and happened mainly while the dose was being raised.

    What the Trial Does Not Tell You

    The trial was open-label, funded by Eli Lilly, and did not include people with type 2 diabetes. Averages describe groups, not you, so bring these numbers to your prescriber rather than treating them as a verdict.

    Dose Steps Listed on Each Label

    Quoted from the FDA labels so the numbers make sense. These are each label's own schedule, not a recommendation or a plan for you.

    Wegovy Injection Steps

    The Wegovy label lists 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12 and 1.7 mg for weeks 13 to 16. For adult weight reduction the maintenance step is 1.7 mg or 2.4 mg, with 2.4 mg recommended and 7.2 mg listed as a maximum for some adults.

    Wegovy Tablet Steps

    Wegovy tablets start at 1.5 mg once daily for 30 days, then 4 mg and 9 mg for 30 days each. From day 91 the label lists 25 mg once daily as the maintenance dosage.

    Zepbound Steps

    The Zepbound label starts at 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks on each dose. The maintenance dose for weight reduction is 5 mg, 10 mg or 15 mg, and 15 mg is the maximum.

    Why the Milligram Numbers Can't Be Compared

    Semaglutide and tirzepatide are different molecules, and milligram amounts of different molecules can't be compared. There is no conversion between them, and your prescriber sets every step.

    Common Side Effects on Each Label

    Placebo-controlled numbers from each label's weight-reduction trials, each read against its own placebo.

    Side effectWegovy 2.4 mg vs placeboZepbound vs placebo
    Nausea44% vs 16%25-29% vs 8%
    Diarrhea30% vs 16%19-23% vs 8%
    Constipation24% vs 11%11-17% vs 5%
    Vomiting24% vs 6%8-13% vs 2%
    Stomach pain20% vs 10%9-10% vs 5%
    Stopped because of side effects6.8% vs 3.2%4.8-6.7% vs 3.4%

    How Many People Stopped

    About 6.8% of people on Wegovy 2.4 mg stopped because of side effects, compared with 3.2% on placebo. On Zepbound, 4.8% to 6.7% stopped depending on dose, compared with 3.4% on placebo.

    Why the Label Tables Differ

    Each label's numbers come from its own trials with different people and doses. They show what each label reports, not how one person would feel on each.

    Full Breakdowns for Each Brand

    The GLP-1 side effects guide sets out both labels' full tables and the warning signs to act on.

    The Boxed Warning and Other Shared Risks

    Both medicines share most of their serious warnings.

    Boxed Warning: Thyroid C-Cell Tumors

    Both labels carry a boxed warning because the active ingredient caused thyroid C-cell tumors in rodents, and it is unknown whether this happens in people. Neither should be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with multiple endocrine neoplasia syndrome type 2 (MEN 2). Report a lump or swelling in the neck, trouble swallowing, hoarseness or shortness of breath.

    Pancreatitis, Gallbladder and Kidneys

    Both labels list acute pancreatitis, gallbladder disease and kidney injury linked to fluid loss from vomiting or diarrhea. Neither is recommended for people with severe gastroparesis.

    Low Blood Sugar and Eye Changes

    Low blood sugar is more likely when either is used with insulin or a sulfonylurea. Both labels also mention diabetic eye complications in people with type 2 diabetes.

    Birth Control Pills and Procedures

    The Zepbound label includes a note for people who use birth control pills, so ask your prescriber what it means for you. Both labels ask you to tell your care team about any planned surgery that uses anesthesia or deep sedation.

    Track Either Medicine in Pep AI

    Once the prescriber decides, the daily work begins.

    Quick Logging and Site Rotation

    Pep AI logs a weekly Wegovy or Zepbound shot in a couple of taps, or a daily tablet with its own schedule, along with step-ups. The body map shows where your recent shots went, so rotating sites is simple. See the Wegovy tracker and the Zepbound tracker.

    Reminders on Your Lock Screen

    Pep AI sends shot-day reminders that show on your Lock Screen, and a daily tablet gets its own schedule. On iPhone, home-screen widgets, a Lock Screen Live Activity and an Apple Watch app show what is due at a glance.

    Symptoms, Day by Day

    Pep AI's side-effect log has a built-in list of GLP-1 symptoms, plus your own, each rated for severity on the day you log it. Your dose history keeps its dates too, so you can check a rough patch against when your step changed.

    Protein and Fiber on Small Portions

    Pep AI logs meals by photo scan, barcode, restaurant menu scan or search and puts estimated protein, fiber and water first. Smaller appetites still need enough of each, and your daily goals keep that in view. More in the protein tracker.

    Your Weight Trend Over Months

    Pep AI keeps your weight trend and progress photos together, and can read weight from Apple Health on iPhone or Health Connect on Android. The line shows months of change, not one morning on the scale.

    Key takeaways

    • Wegovy (semaglutide) acts on GLP-1; Zepbound (tirzepatide) acts on GIP and GLP-1. Both labels cover long-term weight reduction.
    • Wegovy adds heart risk reduction and MASH; Zepbound adds obstructive sleep apnea in adults with obesity.
    • In SURMOUNT-5, an open-label Lilly-funded trial without people with diabetes, average weight loss at 72 weeks was larger with tirzepatide.
    • Milligram amounts of different molecules can't be compared. They are not taken together.
    • Which medicine and any switch are your prescriber's decision.

    Whatever your prescriber decides, keep the record.

    Doses, side effects, meals and weight for any GLP-1 brand, in one app. Pep AI is free to try on iPhone and Android: a free download with a 3-day free trial, then a subscription.

    Download on the App StoreGet it on Google Play

    Frequently asked questions

    Keep reading

    Sources

    1. Wegovy (semaglutide) prescribing information and Medication Guide, Novo Nordisk / FDA (revised 06/2026)
    2. Zepbound (tirzepatide) prescribing information and Medication Guide, Eli Lilly / FDA (revised 08/2026)
    3. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36

    This page compares FDA prescribing information and published trials for general information. It is not medical advice and does not tell you which medicine or dose to take; that decision belongs to you and your prescriber. Dose steps are quoted from each label's own schedule, not as a plan for you. Pep AI is not affiliated with Novo Nordisk or Eli Lilly, and brand names are trademarks of their owners. If a symptom is severe or worrying you, contact your healthcare provider. In an emergency, call 911.

    Published by the Pep AI team · Updated November 2026